Tirzepatide (20mg)
$179.99
Tirzepatide is a synthetic 39-amino-acid peptide functioning as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. In research settings, Tirzepatide is studied for its simultaneous engagement of two incretin receptor pathways and the resulting downstream metabolic signaling interactions.
BioRhex supplies Tirzepatide as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.
- In stock
- COA-verified
- ≥99% purity.
- USA manufactured.
- In stock
- COA-verified
- ≥99% purity.
- USA manufactured.
- COA-verified
- In stock
- ≥99% purity.
- USA manufactured.
What Is Tirzepatide?
Tirzepatide is a synthetic 39-amino-acid peptide functioning as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. In research settings, Tirzepatide is studied for its simultaneous engagement of two incretin receptor pathways and the resulting downstream metabolic signaling interactions.
BioRhex supplies Tirzepatide as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.
Compound Overview
Tirzepatide is a dual incretin receptor agonist studied for its co-activation of GIP-R and GLP-1R signaling pathways. Preclinical research models examine how Tirzepatide may influence:
• Simultaneous GIP receptor and GLP-1 receptor activation and downstream signaling
• Pancreatic insulin and glucagon regulatory pathway interactions
• Hypothalamic energy balance and appetite pathway signaling modeling
• Hepatic lipid metabolism and gluconeogenesis pathway research
• Adipose tissue metabolic signaling and lipid storage pathway models
All findings referenced are from controlled research environments and do not represent clinical outcomes or therapeutic claims.
History of Tirzepatide
Tirzepatide was developed by Eli Lilly as part of research into dual incretin receptor agonism. The rationale was based on research suggesting that combining GIP and GLP-1 receptor activation could produce complementary metabolic signaling effects compared to GLP-1 receptor agonism alone.
Its structure incorporates fatty acid conjugation to extend half-life and enable sustained dual receptor engagement, making it suitable for studying chronic incretin pathway modulation in research settings.
Tirzepatide represents a significant development in dual incretin pharmacology research and continues to be investigated across multiple metabolic pathway biology models.
Molecular Structure
Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Tyr-Leu-Asp-Lys(C20 fatty diacid)-Gln-Ala-Ala-Gln-Glu-Phe-Val-Lys-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂
Research Findings
Published and preclinical research on Tirzepatide covers several areas of scientific investigation, including:
Dual incretin receptor pharmacology: Studies examine Tirzepatide’s comparative binding affinity and activation potency at GIP-R and GLP-1R in receptor expression systems.
Incretin co-activation signaling: Research investigates cAMP accumulation and downstream pathway interactions when both incretin receptors are simultaneously activated.
Pancreatic biology research: Laboratory models evaluate insulin secretion and glucagon suppression patterns in dual incretin agonism research.
Metabolic pathway interactions: Studies explore Tirzepatide’s effects on hepatic and adipose tissue metabolic signaling in preclinical models.
All findings referenced are from controlled, non-clinical research models and do not imply therapeutic or clinical application.
References
FAQ
Q: What type of research is Tirzepatide used for?
Q: What type of research is Tirzepatide used for?
A: Tirzepatide is used in laboratory research settings. All supplied compounds are intended strictly for in vitro and preclinical research purposes. Use is limited to controlled scientific environments.
Q: Where is BioRhex’s Tirzepatide manufactured?
Q: Where is BioRhex’s Tirzepatide manufactured?
A: All BioRhex compounds, including Tirzepatide, are manufactured in a GMP-compliant facility located in the United States.
Q: What testing does BioRhex conduct on Tirzepatide?
Q: What testing does BioRhex conduct on Tirzepatide?
A: Every batch of Tirzepatide undergoes third-party HPLC purity testing, mass spectrometry identity verification, and sterility testing. A Certificate of Analysis is included with every order, documenting batch-specific purity data at a ≥99% threshold.
Q: Is Tirzepatide approved for human use?
Q: Is Tirzepatide approved for human use?
A: No. Tirzepatide is not FDA-approved and is not intended for human or animal administration. It is supplied exclusively for laboratory research purposes.
Q: Who should handle this compound?
Q: Who should handle this compound?
A: Only qualified personnel in controlled laboratory settings following appropriate safety and handling protocols.
Research Use Only
All BioRhex compounds are supplied strictly for laboratory research purposes. Not for human or animal consumption, medical use, or therapeutic application. Tirzepatide is not FDA-approved for any medical purpose. Nothing on this page should be interpreted as health guidance or applied outside controlled research settings.
RELATED PRODUCTS
AOD9604 (5mg)
BPC-157
BPC-157 + TB-500
CJC (no DAC) + Ipamorelin (10mg)
